Pulmatrix, Inc. (PULM): Price and Financial Metrics
PULM Price/Volume Stats
| Current price | $1.96 | 52-week high | $3.14 |
| Prev. close | $2.09 | 52-week low | $1.55 |
| Day low | $1.91 | Volume | 31,000 |
| Day high | $2.09 | Avg. volume | 18,261 |
| 50-day MA | $1.84 | Dividend yield | N/A |
| 200-day MA | $2.06 | Market Cap | 7.16M |
PULM Stock Price Chart Interactive Chart >
Pulmatrix, Inc. (PULM) Company Bio
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company was founded in 2003 and is based in Lexington, Massachusetts.
Latest PULM News From Around the Web
Below are the latest news stories about PULMATRIX INC that investors may wish to consider to help them evaluate PULM as an investment opportunity.
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate UpdatePulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2023 and provided a corporate update on its development programs. |
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute MigrainePulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced the U.S. Food and Drug Administration ("FDA") has accepted the PUR3100 investigational new drug ("IND") application and the Company has received a study may proceed letter for a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Eval |
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled ItraconazolePulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology. PUR1900 is an orally inhaled dry powder formulation of the antifungal itraconazole, utilizing iSPERSE technology, being developed for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with asthma. |
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatePulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2023 and provided a corporate update on its development programs. |
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute MigrainePulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease, today announced the submission of an investigational new drug ("IND") application to the United States Food and Drug Administration ("FDA") for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE"), under development to treat acute migraine. The PUR3100 formulatio |
PULM Price Returns
| 1-mo | 18.95% |
| 3-mo | 10.73% |
| 6-mo | 4.26% |
| 1-year | -32.65% |
| 3-year | -89.35% |
| 5-year | -90.49% |
| YTD | 5.38% |
| 2023 | -52.06% |
| 2022 | -55.67% |
| 2021 | -63.23% |
| 2020 | 38.37% |
| 2019 | -64.17% |
Continue Researching PULM
Want to do more research on Pulmatrix Inc's stock and its price? Try the links below:Pulmatrix Inc (PULM) Stock Price | Nasdaq
Pulmatrix Inc (PULM) Stock Quote, History and News - Yahoo Finance
Pulmatrix Inc (PULM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...